Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (621-630 of 1,058) with videos related to

Pageof 106
Sort By:
Blood|September 7, 2013
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homingJason A Dubovsky, Danielle L Chappell, Bonnie K Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studiesJennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
European Journal of Medicinal Chemistry|April 18, 2023
Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradationRobert J Tokarski, Chia M Sharpe, Andrew C Huntsman, et al.
Cancer Research|June 20, 2012
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemiaConstance Baer, Rainer Claus, Lukas P Frenzel, et al.
Cancer Research|September 29, 1998
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtypeC D Bloomfield, D Lawrence, J C Byrd, et al.
British Journal of Haematology|August 2, 2016
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemiaBhavana Bhatnagar, Ann-Kathrin Eisfeld, Deedra Nicolet, et al.
The AAPS Journal|July 14, 2010
A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo applicationKenneth K Chan, Zhongfa Liu, Zhiliang Xie, et al.
Journal of Hematology & Oncology|February 25, 2021
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLLTimothy L Chen, Bonnie Harrington, Jean Truxall, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2000
Enhanced pneumocystis carinii activity of new primaquine analoguesT E Goodwin, C J Boylan, W L Current, et al.
Blood Advances|April 17, 2019
Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signalingJ T Greene, Rajeswaran Mani, Rahul Ramaswamy, et al.
Pageof 106

Showing results (621-630 of 1,058) with videos related to

Sort By:
Pageof 106
Blood|September 7, 2013
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homingJason A Dubovsky, Danielle L Chappell, Bonnie K Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studiesJennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
European Journal of Medicinal Chemistry|April 18, 2023
Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradationRobert J Tokarski, Chia M Sharpe, Andrew C Huntsman, et al.
Cancer Research|June 20, 2012
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemiaConstance Baer, Rainer Claus, Lukas P Frenzel, et al.
Cancer Research|September 29, 1998
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtypeC D Bloomfield, D Lawrence, J C Byrd, et al.
British Journal of Haematology|August 2, 2016
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemiaBhavana Bhatnagar, Ann-Kathrin Eisfeld, Deedra Nicolet, et al.
The AAPS Journal|July 14, 2010
A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo applicationKenneth K Chan, Zhongfa Liu, Zhiliang Xie, et al.
Journal of Hematology & Oncology|February 25, 2021
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLLTimothy L Chen, Bonnie Harrington, Jean Truxall, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2000
Enhanced pneumocystis carinii activity of new primaquine analoguesT E Goodwin, C J Boylan, W L Current, et al.
Blood Advances|April 17, 2019
Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signalingJ T Greene, Rajeswaran Mani, Rahul Ramaswamy, et al.
Pageof 106